Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Public ClinicalTrials.gov record NCT03604198. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
Study identification
- NCT ID
- NCT03604198
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 125 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 7, 2018 (Actual)
- Primary completion
- Dec 2026 (Estimated)
- Completion
- Dec 2026 (Estimated)
- Last update posted
- Oct 9, 2026
2018 – 2026
United States locations
- U.S. sites
- 25
- U.S. states
- 19
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 49 | Phoenix | Arizona | 85013 | — |
| Site 35 | Stanford | California | 94305 | — |
| Site 39 | Torrance | California | 90502 | — |
| Site 50 | Miami | Florida | 33136 | — |
| Site 10 | Atlanta | Georgia | 30318 | — |
| Site 9 | Chicago | Illinois | 60611 | — |
| Site 1 | Indianapolis | Indiana | 46202 | — |
| Site 5 | Metairie | Louisiana | 70006 | — |
| Site 27 | Baltimore | Maryland | 21287 | — |
| Site 13 | Fall River | Massachusetts | 02721 | — |
| Site 8 | Ann Arbor | Michigan | 48109 | — |
| Site 36 | Rochester | Minnesota | 55905 | — |
| Site 34 | Jackson | Mississippi | 39202 | — |
| Site 3 | St Louis | Missouri | 63110 | — |
| Site 55 | Reno | Nevada | 89511 | — |
| Site 6 | Albany | New York | 12206 | — |
| Site 24 | New York | New York | 10021 | — |
| Site 4 | Wilmington | North Carolina | 28401 | — |
| Site 43 | Cleveland | Ohio | 44195 | — |
| Site 2 | Pittsburgh | Pennsylvania | 15212 | — |
| Site 46 | Pittsburgh | Pennsylvania | 15213 | — |
| Site 11 | Dallas | Texas | 75390 | — |
| Site 7 | El Paso | Texas | 79935 | — |
| Site 32 | Fort Worth | Texas | 76132 | — |
| Site 12 | Houston | Texas | 77079 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03604198, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 9, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03604198 live on ClinicalTrials.gov.